The GCTP Team
Our Chief Scientific Officer, Professor John JV McMurray, is one of the world’s key opinion leaders in the field of clinical trials. Under his leadership the GCTP team have developed comprehensive expertise in the design, conduct and analysis of clinical trials.
Professor John McMurray
Our Chief Scientific Officer Professor John McMurray is renowned as a global leader in clinical trials and active clinical cardiolgist. He is in the top 1% of cited researchers in the world according to the Thomson Reuters Highly Cited Researchers list. As the principal investigator or member of the executive committee or steering committee he has conducted large multi-centre, multi-national trials in CV diseases, renal disease and diabetes. His expertise, especially in the field of heart failure, is routinely sought by major pharmaceutical companies particularly on the design and conduct of clinical trials. His contribution to the field of cardiovascular research was recognised by the award of the 2015 Arrigo Recordati International Prize for Scientific Research. He served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at the Brigham and Women’s Hospital, Boston, USA, and visiting Professor of Medicine, Harvard University, Boston, in 2010/2011. He is also Past-President of the Heart Failure Association of the European Society of Cardiology (ESC). In addition, he sits on the editorial board of the New England Journal of Medicine as well as numerous other cardiovascular journals. View Professor McMurray’s publications
Dr Pardeep Jhund
Dr Pardeep Jhund is a clinical and academic cardiologist. He has extensive experience of the design and conduct of clinical trials and endpoint committees. His academic interests focus on clinical trials and the epidemiology of cardiovascular disease. Pardeep uses large scale health care record datasets to try and understand the modern epidemiology of cardiovascular disease and has first-hand experience of analysing multiple health care records systems. He has published over 70 paper in high impact factor cardiovascular journals. In addition to conducting and analysing clinical trials, he also teaches on educational courses on clinical trials methods around the world. Pardeep is able to use his knowledge of clinical trials, epidemiology and statistics and merge these with his clinical experience to bring a unique set of skills to the company. View Dr Jhund’s Publications
Professor Mark Petrie
Professor Mark Petrie is an experienced academic and clinical cardiologist specialising in advanced heart failure and percutaneous coronary intervention. Mark’s CEC and clinical trial experience began 20 years ago and has steadily increased in volume since. He has chaired or been a member of numerous CECs for a diverse range of trials, companies and with a variety of CROs. He is active in clinical cardiovascular research working with many international teams to deliver high calibre clinical trials. He has published over 100 original articles in high impact factor journals such as NEJM, JACC, Circulation and European Heart Journal. Mark was one of 2 cardiologists on the Writing Group of the 2011 ESC Guidelines for NSTEMI and one of 3 UK reviewers of the 2016 ESC Guidelines for Acute and Chronic Heart Failure. View Professor Petrie’s publications
Dr Michael MacDonald
Dr Michael MacDonald is a clinical cardiologist with extensive experience in CEC management. In addition to his business and project management experience he brings with him, deep clinical trial knowledge developed over the last 12 years, from trial design and analysis to committee set up and organisation. He has chaired and been a member of numerous CECs covering a wide spectrum of diseases. He maintains an academic interest in cardiovascular disease and has published numerous papers in high impact cardiovascular journals. View Dr MacDonald’s Publications
Dr Eugene Connolly
Dr Eugene Connolly is a cardiologist and with a special expertise in the operational aspects of the adjudication process for clinical trials. His expertise includes developing developing charters and endpoint definitions and ensuring processes are compliant with the latest guidance from regulatory bodies such as the FDA. He is responsible for the operation of the team’s Clinical Events Committees (CECs). He has managed the CEC activities of many international clinical trials and has worked with numerous CROs. He has also served as a clinical investigator for numerous studies.